Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think results due april 12th. Update was ‘ahead of market expectations so go knows what the sp is all about. Topped up this am. They are not sells they are buys@ 1.0214. I bought plenty not at £1.06 though. Another mystery of the market!
Any follow up by The Times? If not a positive one must be due.
Agreed. I'm in now. As you say it's not cheap, but looks to be in a promising spot, and the level of director buying is encouraging. Tbh I can't remember how it came to notice - which maybe says it all.
Good to see a few director purchases. 53,000 between 5.
I thinks its pretty much accepted that companies pay ‘over the odds ‘ for an earnings enhancing acquisition’. However this is a loss making enhancing acquisition at the moment . however the combination of the two could provide that lovely financial phrase ‘ accelerated growth’ by the skip load. It is risky in this environment. The trouble is opportunities dont often wait or ending up being much more expensive. There is no safe route in speculation. You either back the managements experience or not . It seems there are one or more exiting. i’ve been patient in getting in here. This is very volatile due to the low share count and low market cap. I like the potential especially at this price which is not cheap. It could get a lot more expensive very quickly and stock is not available in abundance as I discovered last week when I first tried to buy in.
Looks like they paid over the odds to establish an early position in this market which they believe to be strategically important and have strong growth potential. The company lost £2.1m last year and the acquisition takes £3m out the balance sheet so I would like to see further clarity on cash flow before I add further
Might have been better to buy in two parts . Make a second payment performance related which has been popular with small companies recently. On the other hand it’s done and dusted and cog get all the revenue . Shows confidence. I think there is obviously a seller out there who has been active for a while taking advantage of this news. When you think this hit £1.87 last year and the progress in the last couple of months seems a bit weird to me. We know the next set of figures are in line with plenty of growth to follow.
Like it!
I was surprised by the fall back. Thought I’d missed the boat after the Chinese announcement, but fortunately managed to wrestle some off the market makers yesterday morning at a decent price, although I didn’t get my £1.12 order filled. Seems to be a persistent seller recently not quite finished yet. Watch out between1 and 2 this afternoon. Seems to be when a few sell trades come in. I can’t think why the potential looks better than when the stock hit well over£1.50
Nice one!
Today I buy COG at 122.35p but is a sell.
loads
Good news. In a slightly different medical area to our normal work as well?
A few more chunks this afternoon. Yum yum.
yes, so did I.
On track - share price dip overdone on very thin trading. Just helped myself to a few more.
· Growth in revenue of 31% to £5.9 million (H1 2021: £4.5 million)
· Profit after tax in line with expectations at £0.02 million (H1 2021: £0.1 million)
· Continued growth in cash balances to £8.6 million at 30 June 2022 (31 December 2021: £6.8 million)
· Increase in like-for-like sales orders of 44% to £7.2 million (H1 2021: £8.6 million including £3.6 million of one-off orders)
· Increase in contracted order book of £1.5 million to £18.6 million (31 December 2021: £17.1 million)
Operational highlights
· Strengthened senior leadership team with the appointment of a Chief Financial Officer and a Chief Scientist
· Entered a new therapeutic area for the Company, PTSD
· Launched an Alzheimer’s validation study for the Company’s voice-based cognitive assessment solution
Commenting on the results Matthew Stork, Chief Executive Officer of Cambridge Cognition, said: “I am delighted with our continued progress over the last six months. Our contracted order book is at its highest level and, along with a healthy sales order pipeline and strong cash generation, puts us in a great position to continue to invest in strategies to grow the business further.”
Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2022.
The Company followed its strong performance in 2021 with a 31% growth in revenues to £5.9million in the first half of 2022 (H1 2021: £4.5 million). Order intake was in line with the Board’s expectations at £7.2 million, up 44% on a like-for-like basis on H1 2021 (H1 2021:£8.6 million, including £3.6 million of one-off orders) and the Company has a growing, qualified pipeline of opportunities for the second half of 2022.
The contracted order book was £18.6 million at 30 June 2022 increasing from £17.1m at 31 December 2021. The order book provides the Company with visibility over future revenues and provides a solid foundation from which the Company can continue to invest in product and commercial development to further expand the business.
Trading conditions continue to be positive, and the Company has high levels of engagement with existing and potential new clients. With continued investment in commercial activities and product development, the Company expects to achieve further year-on-year revenue growth. The cash position continued to grow to £8.6 million at 30 June 2022 and provides the business with the platform to make considered investments as opportunities arise.
Results in a week and the share price has awakened. Has someone heard positive things ahead of time?
And another. Would be nice if the market could play along but not an issue as this should go in the LTH category.
And just like that the share price is back to 120p. Bit of a downtrend here isn’t there despite the director buys and new contracts?
Excellent news - so happy to invest here! Keep up the excellent work CamCog.
Nice to see a bit of positive news off the back of the options. I know what people are saying about directors not investing their own funds but putting yourself in their shoes why would you if you can do it via a cheaper route?
They may be confident that it will not effect shareholder confidence in the long run because their is a big pipeline of positive news flow.
Nice to see we are still working alongside top 10 pharmas.
Also I have a feeling the US department of defence might not be short of spare cash So hopefully we can take this partnership further!